News | August 26, 2024
Akums Q1 FY25 revenue up 5.1%
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise
MoCRA mandates that all facilities involved in the manufacturing and processing of cosmetic products for sale in the United States
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
Subscribe To Our Newsletter & Stay Updated
